LT-106-175 (CAS: 1429515-49-0 )
Background Information of LT-106-175
LT-106-175, a multiple kinases inhibitor, shows potent inhibitory activities against CDKs and FLT3 with IC50s of 0.60±0.11 nM, 3.33±0.25 nM, and 9.10±0.16 nM for FLT3, CDK6, and CDK2, respectively. Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy.
Storage Condition of LT-106-175
Quality Control and Spectral Data
Mechanism and Indications
||Sponsor & Collaborators
Structure Information of LT-106-175
Other Form Products of LT-106-175
Recommended Products in Same Target
Recommended Products in the Same Indication
Safety Data of LT-106-175
Chemical and Physical Properties
.Zhi Y, et al. Discovery of the selective and efficacious inhibitors of FLT3 mutations. Eur J Med Chem. 2018 Jun 5;155:303-315.
Fms-like tyrosine kinase 3 (FLT3) is among the most frequently mutated protein in acute myeloid leukemia (AML), which has been confirmed as an important drug target for AML chemotherapy. Starting from the lead compound LT-106-175, a series of 1-H-pyrazole-3-carboxamide derivatives were synthesized to improve the FLT3 inhibitory potency and selectivity. Among them, compound 50 was identified as a highly potent and selective FLT3 inhibitor (IC50 = 0.213 nM), which showed equal activities against various mutants of FLT3 including FLT3 (ITD)-D835V and FLT3 (ITD)-F691L that is resistant to quizartinib. Compound 50 also exhibited efficacy against the human AML cell line MV4-11 (IC50 = 16.1 nM) harboring FLT3-ITD mutants. Inversely, compound 50 displayed no cytotoxicity to FLT3-independent cells, and the biochemical analyses showed that its effects were related to the inhibition of FLT3 signal pathways. Additionally, compound 50 induced apoptosis in MV4-11 cell as demonstrated by flow cytometry. Moreover, compound 50 showed enhanced metabolic stability. Altogether, it was concluded that compound 50 could be a promising FLT3 inhibitor for further developing therapeutic remedy of AML.